Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Financial Officer

Chief Technical Officer

Chief Medical Officer

General Counsel/Secretary

Chief Technology Officer

Chief Scientific Officer

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers wit...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-08	Premium	bought	Premium	Premium	Premium	-
2024-03-28	Premium	bought	Premium	Premium	Premium	-
2024-02-23	Premium	bought	Premium	Premium	Premium	-
2024-02-23	Premium	bought	Premium	Premium	Premium	-
2024-02-23	Premium	sold	Premium	Premium	Premium	-
2024-01-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2024-01-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2024-01-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Technical Officer
2024-01-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2024-01-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2024-01-03	Premium	sold (taxes)	Premium	Premium	Premium	General Counsel/Secretary
2023-07-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2023-07-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Technology Officer
2023-07-03	Premium	sold (taxes)	Premium	Premium	Premium	General Counsel/Secretary
2023-07-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Financial Officer
2023-07-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Executive Officer
2023-07-03	Premium	sold (taxes)	Premium	Premium	Premium	Chief Medical Officer
2023-06-14	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer
2023-06-12	Premium	bought	Premium	Premium	Premium	Chief Scientific Officer
2023-04-14	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-04-14	Premium	bought	Premium	Premium	Premium	Chief Medical Officer
2023-04-13	Premium	bought	Premium	Premium	Premium	Chief Medical Officer
2023-04-13	Premium	bought	Premium	Premium	Premium	Chief Financial Officer
2023-04-13	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-04-13	Premium	bought	Premium	Premium	Premium	General Counsel/Secretary

ONCT - Oncternal Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ONCT